🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: BI 201335 NA

Found 15 matching trials

Antiviral Effect, Safety, and Pharmacokinetics of BI201335 +PegIFN/RBV in HCV-GT1 (SILEN-C1&2)

PHASE2

The objective was to investigate the antiviral effect, safety, and pharmaco...

Status

Completed

Location

1220.5.0001 Boehringer Ingelheim Investigational Site

Start Date

2008-10

Trial ID

NCT00774397

Treatments Being Tested

BI 201335 NA 240 mg QD / LI PegIFN/RBV BI 201335 NA 120mg QD / LI PegIFN/RBV BI 201335 NA 240 mg QD PegIFN/RBV BI 201335 NA 240 mg QD PegIFN/RBV BI 201335 NA 240 mg BID PegIFN/RBV PegIFN/RBV BI 201335 NA 240 mg QD PegIFN/RBV Placebo

Safety, Tolerability, and Pharmacokinetics of BI 201335 NA in Healthy Male Subjects

PHASE1

The objective of this trial was to investigate safety, tolerability, and ph...

Status

Completed

Location

Multiple Locations

Start Date

2008-04

Trial ID

NCT02182297

Treatments Being Tested

BI 201335 NA in single rising doses Placebo

This Trial Evaluates Safety, Pharmacokinetic Profile and Anti-viral Response of BI 207127 and BI 201335 for Patients With Chronic Hepatitis C

PHASE2

The objective of this trial is to investigate tolerability, safety, pharmac...

Status

Completed

Location

1241.25.002 Boehringer Ingelheim Investigational Site

Start Date

2012-02

Trial ID

NCT01528735

Treatments Being Tested

BI 207127 NA peginterferon Ribavirin Ribavirin BI 207127 NA BI 201335 NA BI 201335 NA peginterferon

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 201335 as Softgel Capsule in Naive Hepatitis C Virus (HCV) Patients

PHASE2

The current Standard of Care (SOC) for chronic HCV infection, which is pegy...

Status

Completed

Location

1220.14.003 Boehringer Ingelheim Investigational Site

Start Date

2009-07

Trial ID

NCT00947349

Treatments Being Tested

ribavirin (RBV)pegylated interferon (PegIFN) alfa-2a pegylated interferon (PegIFN) alfa-2a ribavirin (RBV)BI 201335 NA low placebo pegylated interferon (PegIFN) alfa-2a ribavirin (RBV)BI 201335 NA high BI 201335 NA low BI 201335 NA high placebo BI 201335 NA high Placebo

Bioequivalence Trial of 2 Dose Strengths of BI 201335 NA Soft Gelatine Capsules

PHASE1

The objective is to investigate the bioequivalence of 2 dose strengths of 4...

Status

Completed

Location

1220.53.08101 Boehringer Ingelheim Investigational Site

Start Date

2012-10

Trial ID

NCT01704846

Treatments Being Tested

BI 201335 NA 120 mg capsule BI 201335 NA 120 mg capsule BI 201335 NA 40 mg capsule BI 201335 NA 40 mg capsule

Japanese Pegylated Interferon (PegIFN) Alfa-2b/Ribavirin (RBV) Combination Trial

PHASE3

The aim of this trial is to evaluate the safety and efficacy of BI 201335 g...

Status

Completed

Location

1220.54.08104 Boehringer Ingelheim Investigational Site

Start Date

2012-04

Trial ID

NCT01579474

Treatments Being Tested

BI 201335 high dose BI 201335 low dose BI 201335 high dose BI 201335 high dose

Safety, Tolerance, and Pharmacokinetics of Single Oral Doses of BI 201335 NA and Bioavailability in Healthy Male Subjects

PHASE1

The objective of this study was to investigate the safety, tolerability, an...

Status

Completed

Location

Multiple Locations

Start Date

2006-09

Trial ID

NCT02182323

Treatments Being Tested

BI 201335 NA Placebo solution

Effect of BI 201335 Mediated UGT1A1 (Uridine-diphosphate-glucuronosyltransferases) Inhibition in Healthy Volunteers

PHASE1

Study to investigate the effect of UGT1A1 inhibition by single and multiple...

Status

Completed

Location

Multiple Locations

Start Date

2010-01

Trial ID

NCT02182375

Treatments Being Tested

BI 201335 NA Raltegravir

Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced

PHASE1

This study will investigate safety, antiviral activity, and pharmacokinetic...

Status

Completed

Location

1220.2.10 Boehringer Ingelheim Investigational Site

Start Date

2007-09

Trial ID

NCT00793793

Treatments Being Tested

BI201335 BI201335 BI201335 BI201335 Placebo

Bioavailability of Soft Gelatin Capsule Formulation of BI 201335 NA Compared to the Solution Formulation in Healthy Volunteers

PHASE1

The objective of this study was to establish the relative bioavailability o...

Status

Completed

Location

Multiple Locations

Start Date

2008-01

Trial ID

NCT02182284

Treatments Being Tested

low dose BI 201335 NA soft gelatine capsule (SGC)high dose BI 201335 NA soft gelatine capsule (SGC)low dose BI 201335 NA powder in bottle (PIB)high dose BI 201335 NA powder in bottle (PIB)

Previous Next